Diabetes mellitus and islet cell specific autoimmunity as adverse effects of immunsuppressive therapy by FK506/Tacrolimus

Experimental and Clinical Endocrinology and Diabetes

Volumn 108, Issue 5, 2000, Pages 347-352

  Lohmann, T ^a   List, C ^a   Lamesch, P ^a   Kohlhaw, K ^a   Wenzke, M ^a   Schwarz, C ^a   Richter, O ^a   Hauss, J ^a   Seissler, J ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Diabetes mellitus; ICA; Tacrolismus FK506

Indexed keywords

AUTOANTIBODY; C PEPTIDE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INSULIN; PREDNISOLONE; TACROLIMUS;

ADULT; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; GRAFT REJECTION; HUMAN; HYPOINSULINEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSULIN RESISTANCE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; PANCREAS ISLET CELL; PRIORITY JOURNAL;

ADULT; AUTOIMMUNITY; BLOOD GLUCOSE; C-PEPTIDE; CYCLOSPORINE; DIABETES MELLITUS; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISLETS OF LANGERHANS; LIPIDS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; TACROLIMUS;

EID: 0033855402     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-8127     Document Type: Article

References (21)

1. Chelmicka-Schorr E, Wiegmann K, Wollmann R, Arnason BGW, Kim DH: Immunoaugmenting effect of FK 506 on experimental allergic encephalomyelitis in Lewis rats. J Autoimmun 11: 329-334, 1998
2. Esmatjes E, Rodriguez-Villar C, Ricart MJ, Casamitjana RS, Martorell J, Sabater L, Astudillo E, Fernandez-Cruz L: Recurrence of immunological markers for type 1 (insulin-dependent) diabetes mellitus in immunosuppressed patients after pancreas transplantation. Transplantation 66: 128-131, 1998
3. European FK506 Multicentre Liver Study Group: Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 344: 423-428, 1994
4. Ferrannini E: Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev 19: 477-490, 1998
5. Gruessner RW: Tacrolimus in pancreas transplantation: a multicenter analysis. Clin Transplant 11: 299-312, 1997
6. Jaeger C, Brendel MD, Hering BJ, Eckhard M, Bretzel RG: Progressive islet graft failure occurs significantly earlier in autoantibody-positive than in autoantibody-negative IDDM recipients of intrahepatic islet allografts. Diabetes 46: 1907-1910, 1997
7. Jindal RM: Posttransplant diabetes mellitus - a review. Transplantation 58: 1289-1298, 1994
8. Kahn BB: Type 2 diabetes: when insulin secretion fails to compensate for insulin resistance. Cell 92: 593-599, 1998
9. Krentz AJ, Dousset B, Mayer D, McMaster P, Buckels J, Cramb R, Smith JM, Nattrass M: Metabolic effects of cyclosporin A and FK 506 in liver transplant recipients. Diabetes 42: 1753-1759, 1993
10. Lohmann T, Seissler J, Verlohren HJ, Schröder S, Rötger J, Dähn K, Morgenthaler N, Scherbaum WA: Distinct genetic and immunological features in patients with insulin-dependent diabetes below and above age 40 at onset. Diab Care 20: 524-529, 1997
11. Pietropaolo M, Peakman M, Pietropaolo SL, Zanone MM, Foley TP, Becker DJ, Trucco M: Combined analysis of GAD65 and ICA512 (IA-2) autoantibodies in organ and non-organ-specific autoimmune diseases confers high specifity for insulin-dependent diabetes mellitus. J Autoimmun 11: 1-10, 1998
12. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS for the FK506 Kidney Transplant Study Group: A comparison of tacrolimus (FK506) and cyclosporine for immunosupression after cadaveric renal transplantation. Transplantation 64: 977-983, 1997
13. Redmon JB, Olson LK, Armstrong MB, Greene MJ, Robertson PR: Effects of Tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest 98: 2786-2793, 1996
14. Seissler J, De Sonnaville JJJ, Morgenthaler NG, Steinbrenner H, Glawe D, Khoo-Morgenthaler UY, Lan MS, Notkins AL, Heine RJ, Scherbaum WA: Immunological heterogeneity in type I diabetes: presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease. Diabetol 41: 891-897, 1998
15. Steinmüller TM, Gräf K-J, Schleicher J, Leder K, Bechstein WO, Mueller AR, Dette K, Schulz E, Neuhaus P: The effect of FK506 versus cyclosporine on glucose and lipid metabolism - a randomized trial. Transplantation 58: 669-674, 1994
16. Thomson AW, Starzl TE: FK 506 and autoimmune disease: perspective and prospects. Autoimmunity 12: 303-313, 1992
17. Tyden G, Reinholt FP, Sundkvist G, Bolinder J: Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts. N Engl J Med 335: 860-863, 1996
18. Vauhkonen I, Niskanen L, Vanninen E, Kainulainen S, Uusitupa M, Laakso M: Defects in insulin secretion and insulin action in non-insulin-dependent diabetes mellitus are inherited. J Clin Invest 101: 86-96, 1998
19. WHO/ADA: Report of the Expert Commitee on the diagnosis and classification of diabetes mellitus. Diab Care 20: 1183-1197, 1997
20. Wijnen RM, Ericzon BG: Update of tacrolimus in pancreas transplantation. Diabet Med 14: 911-918, 1997
21. Yoshioka K, Sato T, Okada N, Ishii T, Imanishi M, Tanaka S, Kim T, Sugimoto T, Fuji S: Post-transplant diabetes with anti-glutamic acid decarboxylase antibody during tacrolimus therapy. Diab Res Clin Pract 42: 85-89, 1998